Efficacy of Botulinum Toxin Type A for Prevention of Post-Mastectomy Scar in Transmen: A Prospective, Randomized Study

Background: Subcutaneous mastectomies in transmen have been gaining popularity. However, post-operative scars are an inevitable consequence. Recently, Botulinum neurotoxin A (BoNT-A) has shown positive effects in scar prevention. The objective of this study is to investigate the effectiveness of BoN...

Full description

Saved in:
Bibliographic Details
Published in:Toxins Vol. 15; no. 11; p. 636
Main Authors: Winayanuwattikun, Waranaree, Vachiramon, Vasanop, Rattananukrom, Teerapong, Palakornkitti, Pasita, Sitpahul, Ngamcherd
Format: Journal Article
Language:English
Published: Switzerland MDPI AG 31.10.2023
Subjects:
Botulinum toxin
Botulinum toxin type A
Botulinum Toxins, Type A - therapeutic use
Breast Neoplasms
Cicatrices
Cicatrix - etiology
Cicatrix - prevention & control
Dosage and administration
Effectiveness
Evaluation
Female
Gender dysphoria
Gender identity
Humans
injectables
Mastectomy
Mastectomy - adverse effects
Methods
neuromodulators
neurotoxin
Neurotoxins
Patient satisfaction
Placebos
Prevention
Prospective Studies
Scars
Statistical analysis
Surgery
surgical scars
Systematic review
Toxins
Transgender people
Transgender persons
Treatment Outcome
Wound healing
Thailand
injectables
neuromodulators
neurotoxin
surgical scars
ISSN:2072-6651, 2072-6651
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Subcutaneous mastectomies in transmen have been gaining popularity. However, post-operative scars are an inevitable consequence. Recently, Botulinum neurotoxin A (BoNT-A) has shown positive effects in scar prevention. The objective of this study is to investigate the effectiveness of BoNT-A in scar prevention. Methods: Fifteen patients who had undergone subcutaneous mastectomy were included. At 14 days post-surgery, either incoBoNT-A or a placebo was injected into the scar on each side. The primary outcome assessment measured the scar’s severity using the Vancouver Scar Scale (VSS) and the Patient and Observer Scar Assessment Scale (POSAS). The secondary outcome assessment evaluated the scar’s color using a standard measurement device. Outcome assessments were conducted until 6 months post-surgery. Results: There were significantly lower VSS scores in the BoNT-A group compared to the placebo at the end of the study (7.43 ± 0.26 vs. 8.82 ± 0.26, p < 0.001). The objective assessment revealed a statistically significant decrease in redness values in the BoNT-A group compared to the placebo at 3 and 6 months. Conclusion: BoNT-A has demonstrated effectiveness in scar prevention by reducing the severity of postoperative scar formation and improving overall scar appearance.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Undefined-1
ObjectType-Feature-3
content type line 23
ISSN:2072-6651
2072-6651
DOI:10.3390/toxins15110636